Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Vutrisiran Market Size Forecast: How Large Could The Market Become By 2030?
The market for vutrisiran has seen a sharp increase in recent years. Expanding from $0.67 billion in 2025 to $0.75 billion in 2026, it is projected to achieve a compound annual growth rate (CAGR) of 12.1%. Several factors have fueled this expansion historically, including the approval of pioneering siRNA therapies, significant unmet medical requirements in hATTR amyloidosis, the constraints associated with liver transplant procedures, the broadening of orphan drug regulations, and advancements in genetic diagnostic capabilities.
Over the coming years, rapid expansion is anticipated for the vutrisiran market size. By 2030, its valuation is projected to reach $1.18 billion, reflecting a compound annual growth rate (CAGR) of 12.0%. Several factors drive this forecasted growth: heightened awareness of rare diseases, a broadening RNA therapeutics pipeline, greater uptake of long-acting treatments, expanded genetic screening initiatives, and the development of specialty care facilities. Among the key trends shaping the outlook are the rising implementation of RNA interference therapies, a stronger emphasis on rare genetic conditions, the proliferation of dosing regimens with longer intervals, escalating need for amyloidosis-targeted therapies, and more frequent utilization of subcutaneous RNA medications.
Download A Free Sample Report For Comprehensive Market Insights:
Vutrisiran Market Development Factors: Which Trends Are Supporting Demand?
The growth of the vutrisiran market is anticipated to be fueled by rising research and development investments. Research and development involves the systematic exploration and experimentation to create or enhance products, services, or processes. This increased R&D spending is driven by government incentives and funding, along with escalating healthcare and pharmaceutical demands, as well as sustainability and environmental issues. Pharmaceutical companies utilize R&D funding to run clinical trials that confirm a drug’s long-term efficacy and safety, which facilitates broader regulatory approvals. Moreover, progress in RNA interference (RNAi) technology boosts the drug’s accuracy, minimizing side effects and enhancing patient uptake. A case in point is that in April 2025, the Office for National Statistics, a UK government agency, reported that the UK government’s net R&D expenditure hit about US $22.9 billion (£17.4 billion) in 2023, compared to roughly US $20.0 billion (£16.1 billion) in 2022. Consequently, the escalating investment in research and development is propelling the vutrisiran market forward.
Vutrisiran Market Segmentation And Category Breakdown
The vutrisiran market covered in this report is segmented –
1) By Drug Class: RNA Interference (RNAi) Therapeutics, GalNAc-Conjugated Nucleic Acid Drugs, Synthetic RNA-Based Therapeutics
2) By Route Of Administration: Injectable, Subcutaneous
3) By Patient Demographics: Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By RNA Interference (RNAi) Therapeutics: Small Interfering RNA (siRNA) Drugs, Gene-Silencing RNA Therapies
2) By GalNAc-Conjugated Nucleic Acid Drugs: GalNAc-Conjugated siRNA Therapies, Hepatocyte-Targeted RNA Therapeutics
3) By Synthetic RNA-Based Therapeutics: Chemically Modified RNA Therapeutics, Long-Acting RNA Therapeutics
Vutrisiran Market Transformation Trends: Which Innovations Are Driving Change?
Major players in the vutrisiran market are pursuing regulatory approvals to expand the drug’s application to cardiomyopathy, specifically through a supplemental indication for ATTR CM, with the aim of broadening the patient population and enhancing long-term value. A supplemental new drug application (sNDA) serves as a regulatory mechanism that allows an already approved medication to be utilized for additional indications. For example, in March 2025, Alnylam Pharmaceuticals—a biotechnology firm headquartered in the United States—secured FDA approval for AMVUTTRA (vutrisiran) for use in adult patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR-CM). This milestone made vutrisiran the first RNAi therapy approved for both polyneuropathy and cardiomyopathy manifestations of the disease. Consequently, the expansion into cardiomyopathy represents a central trend fueling growth in the vutrisiran market, as it extends the drug’s clinical applicability and expands its reach among patients.
Vutrisiran Market Competitive Analysis Of Major Industry Participants
Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc
Access The Complete Vutrisiran Market Report:
Vutrisiran Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the vutrisiran market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model